Global Hereditary Angioedema Industry Outlook 2025-2029: Market Set to Cross $3.84 Billion Milestone

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Hereditary Angioedema Market Size By 2025?
The overall valuation of the hereditary angioedema sector has witnessed robust expansion over the preceding years, projected to climb from its 2024 figure of $2.62 billion up to $2.81 billion by 2025, reflecting a compound annual growth rate averaging 7.4%. This upward trajectory during the past period is primarily traceable to several factors, including a greater incidence of hereditary angioedema cases, augmented commitment to scientific investigation and development endeavors, a greater volume of successful drug authorizations, the emergence of newer therapeutic products, and a simultaneous rise in the amount of money consumers have available for spending.

How Big Is the Hereditary Angioedema Market Size Expected to Grow by 2029?
Projected for a robust expansion, the hereditary angioedema market is anticipated to reach a valuation of $3.84 billion by the year 2029, exhibiting a compound annual growth rate (CAGR) of 8.1% over the upcoming years. This upward trajectory during the forecast interval is fundamentally driven by several factors, including a higher incidence of infrequent illnesses, escalating healthcare spending, augmented backing originating from charitable entities, heightened public knowledge regarding hereditary angioedema, and a greater emphasis on prompt diagnostic identification. Key movements shaping this market moving forward encompass progress in technology, the creation of innovative treatment modalities, the introduction of newly approved pharmaceuticals, the availability of sophisticated diagnostic instruments, and improvements in genetic screening methodologies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-global-market-report

Which Key Market Drivers Powering Hereditary Angioedema Market Expansion and Growth?
The expanding incidence of uncommon ailments is anticipated to be a catalyst for the expansion of the hereditary angioedema market in the coming period. These infrequent conditions, sometimes termed orphan diseases, represent medical problems impacting only a small fraction of the populace, an increase attributed to factors like advancements in clinical investigation, shifts in demographic profiles, and ecological influences. Hereditary angioedema (HAE) stands out as a notable rare illness, emphasizing the crucial requirement for specialized interventions and heightened recognition given its potentially fatal swelling occurrences; its infrequent and inherited basis underscores the importance of prompt diagnosis and tailored treatments for successful control and better patient results. To illustrate this, data shared by Rare Disease Advisor, a U.S. online information provider for medical professionals, indicated in June 2022 that HAE is observed in roughly one person out of every 50,000, with prevalence figures spanning from one in 10,000 up to one in 150,000; moreover, within the United States alone, HAE events lead to an estimated 15,000 to 30,000 annual visits to emergency departments, consequently establishing the rise in rare disease frequency as a force propelling the hereditary angioedema market forward.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22002&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Hereditary Angioedema Market?
Leading firms within the hereditary angioedema sector are currently focusing on creating novel therapeutics, exemplified by the advancement of oral plasma kallikrein inhibitors, aiming to furnish patients with treatment modalities for acute attacks that offer superior ease of use and efficacy when needed. These inhibitors function by obstructing plasma kallikrein activity, a mechanism crucial for curbing excessive bradykinin release, thereby serving as a primary intervention strategy for managing hereditary angioedema. A notable development in this sphere occurred in September 2024 when KalVista Pharmaceuticals, Inc., a company headquartered in the United States, successfully secured FDA acceptance for its new drug application concerning sebetralstat. This particular oral plasma kallikrein inhibitor, currently under investigation, is slated for use as an on-demand remedy for hereditary angioedema (HAE) episodes in individuals spanning adolescents aged 12 and above, as well as adults, introducing a distinct therapeutic pathway through its specific inhibition of plasma kallikrein function; the receipt of this NDA acceptance signifies a substantial progression point in the process leading to prospective regulatory approval and subsequent market introduction.

What Are the Emerging Segments in the Hereditary Angioedema Market?
The hereditary angioedemamarket covered in this report is segmented -

1) By Type: Hereditary Angioedema Type I; Hereditary Angioedema Type II
2) By Treatment Type: Prophylaxis; On-demand
3) By Drug Class: C-1 Esterase Inhibitors; Bradykynin Receptor Antagonist; Kallikrein Inhibitors; Other Drug Classes
4) By Route Of Administration: Subcutaneous; Intravenous; Oral
5) By Distribution channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Subsegments:

1) By Hereditary Angioedema Type I: C1-Inhibitor Deficiency; Low C1-Inhibitor Levels; Reduced C1-Inhibitor Function
2) By Hereditary Angioedema Type II: Normal C1-Inhibitor Levels; Dysfunctional C1-Inhibitor; Genetic Mutations In SERPING1 Gene

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=22002&type=smp

Who Are the Global Leaders in the Hereditary Angioedema Market?
Major companies operating in the hereditary angioedema market are Intellia Therapeutics Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Otsuka Pharmaceutical Co. Ltd., CSL Limited, Cipla Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Spark Therapeutics Inc., Pharming Group N.V., Pharvaris N.V., Astria Therapeutics Inc., CENTOGENE N.V., KalVista Pharmaceuticals Inc., ADARx Pharmaceuticals Inc., Adverum Biotechnologies Inc., Attune Pharmaceuticals Inc., Lev Pharmaceuticals Inc.

Which are the Top Profitable Regional Markets for the Hereditary Angioedema Industry?
North America was the largest region in the hereditary angioedema market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22002

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.